Skip to main content
SpringerLink
Log in

Galanthamine

A Viewpoint by Henry Brodaty

  • New Drug Profile
  • Guest Commentary
  • Published:
Drugs & Aging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dal-Bianco P, Maly J, Wober C, et al. Galanthamine treatment in Alzheimers disease. J Neural Transm Suppl 1991; 33: 59–63

    PubMed  CAS  Google Scholar 

  2. Rainer M, Mark T, Haushofer A. Galanthamine hydrobromide in the treatment of senile dementia of Alzheimer’s type. In: Kewitz, Thomsen, Bickel, editors. Pharmacological interventions on central cholinergic mechanisms in senile dementia (Alzheimer’s disease). Munich: Zuckschwerdt Verlag 1989: 233–7

    Google Scholar 

  3. Rainer M, Mucke H, Janoch P, et al. Galanthamine treatment in Alzheimer’s disease: the identification of responders [abstract]. Neuropsychopharmacology 1994 May; 10 Suppl. Part 2: 215

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Academic Department of Psychogeriatrics, Prince Henry Hospital, Little Bay, New South Wales, Australia

    Henry Brodaty

Authors
  1. Henry Brodaty
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brodaty, H. Galanthamine. Drugs & Aging 9, 66 (1996). https://doi.org/10.2165/00002512-199609010-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199609010-00007

Keywords

Search

Navigation